An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

ABSTRACT Objective: To evaluate the clinical and biological activity of apremilast in patients with severe plaque-type psoriasis. Research design and methods: Apremilast, a phosphodiesterase‑4 inhibitor, inhibits in vitro activity of multiple inflammatory factors implicated in the pathogenesis of p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current medical research and opinion 2008-05, Vol.24 (5), p.1529-1538
Hauptverfasser:	Gottlieb, A. B., Strober, B., Krueger, J. G., Rohane, P., Zeldis, J. B., Hu, C. C., Kipnis, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - pharmacokinetics Apremilast Biopsy, Needle Confidence Intervals Dose-Response Relationship, Drug Drug Administration Schedule Epidermal thickness Epidermis - drug effects Epidermis - pathology Female Follow-Up Studies Humans Immunohistochemistry Male Middle Aged Phosphodiesterase 4 inhibitor Phosphodiesterase 4 Inhibitors Pilot Projects Psoriasis Psoriasis - drug therapy Psoriasis - pathology Psoriasis Area and Severity Index (PASI) Severity of Illness Index Static Physician's Global Assessment (sPGA) Thalidomide - administration & dosage Thalidomide - analogs & derivatives Thalidomide - pharmacokinetics Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!